Sclerotherapy is a safe method of treatment of chronic venous disorders in older patients: A prospective and comparative study of consecutive patients

• Published in: Phlebology Vol. 32; no. 4; p. 234
• Main Authors: Gillet, Jean-Luc, Desnos, Claudine H, Lausecker, Michel, Daniel, Christian, Guex, Jean-Jerome, Allaert, François-André
• Format: Journal Article
• Language: English
• Published: England 01.05.2017
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants - administration & dosage; Chronic Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors - administration & dosage; Prospective Studies; Sclerotherapy; Varicose Veins - therapy; Venous Thrombosis - therapy; older patients; echo-sclerotherapy; Foam sclerotherapy; sclerotherapy; varicose veins
• ISSN: 1758-1125
• DOI: 10.1177/0268355516642659

Objectives An aging population requires evaluation of methods of treatment for older patients. Our objective was to evaluate the indications, practical modalities, safety and tolerability of sclerotherapy in patients 75 years of age and older (group 1) and compare with a control group of patients 18 to74 years of age (group 2). Method This observational, multicentre, prospective and comparative study was conducted by the French Society of Phlebology. Each centre collected in 10 to 20 patients ≥75 years of age and an equal number of patients <75 years of age treated by sclerotherapy, the treatment indication, the patient's personal history, the CEAP clinical class, the type of the veins being treated, the characteristics of sclerotherapy and the complications (immediately after treatment and at one-month follow-up). Results Population: In total, 418 patients were enrolled in 15 centres: 176 patients in group 1 (mean: 79.4 years) and 242 patients in group 2 (mean: 52.7 years).CEAP clinical classes C4, C5 and C6, history of deep vein thrombosis (12.5%) and superficial vein thrombosis (11.9%), long-term anticoagulant therapy (9.1%) and antiplatelet therapy (16.5%) were more frequent in older patients.All types of veins were treated from saphenous veins to telangiectasias. Sclerotherapy features: There was no difference in concentration of the sclerosing agents. When foam sclerotherapy was used (84% of patients), the injected volume was lower in group 1. One vasovagal syncope occurred in group 1. One asymptomatic distal deep vein thrombosis, confined to the Medial Gastrocnemius Veins, was reported in both groups at one-month follow-up. Conclusions This study shows the feasibility and safety of sclerotherapy in older patients, with no specific complications nor need for special precautions.